Filtered By:
Condition: Hypertension
Nutrition: Calcium

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 337 results found since Jan 2013.

This diet advice could kill you
The American Heart Association says sodium in salt raises blood pressure. They say it increases the risk for heart disease and stroke.  But the latest science says otherwise… A British review of 34 clinical trials showed that cutting down on salt reduced blood pressure only slightly for people with hypertension.1  And a new study in The Lancet found that some low-salt diets could put you at GREATER risk of heart disease and death.2 Researchers analyzed data from 133,118 people. They wanted to see if there was a link between high sodium and heart attack, stroke and death The results were startling. People on “he...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Randall Hall Tags: Health Heart Health Men's Health Nutrition Women's Health Source Type: news

Featured Review: First-line drugs for hypertension
Thiazides best first choice for hypertensionHigh blood pressure or hypertension can increase the risk of heart attacks and stroke. One of the most important decisions in treating people with elevated blood pressure is what drug class to use first. This decision has important consequences in terms of health outcomes and cost.TheCochrane Hypertension Group, which is part ofCochrane Circulation and Breathing, updated their original 2009 Cochrane Review looking at what drug class was the best first-line choice in treating adult patients with raised blood pressure. No new trials were found in the update; keeping the total at 24...
Source: Cochrane News and Events - April 20, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis
Conclusions: Although only ACEIs have evidences showing its effect in reducing cardiovascular events and all secondary outcomes, head-to-head comparisons did not provide strong evidence in difference in the effects between these blood pressure-lowering drugs.
Source: Journal of Hypertension - May 1, 2018 Category: Cardiology Tags: Reviews Source Type: research

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
Publication date: Available online 26 August 2018Source: The LancetAuthor(s): Ajay Gupta, Judith Mackay, Andrew Whitehouse, Thomas Godec, Tim Collier, Stuart Pocock, Neil Poulter, Peter SeverSummaryBackgroundIn patients with hypertension, the long-term cardiovascular and all-cause mortality effects of different blood pressure-lowering regimens and lipid-lowering treatment are not well documented, particularly in clinical trial settings. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study reports mortality outcomes after 16 years of follow-up of the UK participants in the original ASCOT trial.MethodsASCOT was...
Source: The Lancet - August 26, 2018 Category: General Medicine Source Type: research

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
AbstractBlood pressure lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular (CV) events. Drugs acting on the renin –angiotensin–aldosterone system, such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), showed similar benefit on major CV events to other antihypertensive medications. In real-world practice, ARBs reduced by 10% the incidence of CV mortality, non-fata l myocardial infarction, non-fatal stroke and provided superior protection against CV events than ACEIs in high-risk patients. Despite simila...
Source: Advances in Therapy - December 27, 2018 Category: Drugs & Pharmacology Source Type: research

Mediacalcosis in hemodialysis, predictors and prognosis
ConclusionMediacalcosis is a severe complication since it increases the risk of cardiovascular morbidity and mortality in hemodialysis patients, to this end, the individualization of entangled factors involved in its pathophysiology, will slow down or prevent its progression in the future.
Source: Archives of Cardiovascular Diseases Supplements - July 24, 2019 Category: Cardiology Source Type: research

Comparison of First-Line Dual Combination Treatments in Hypertension: Real-World Evidence from Multinational Heterogeneous Cohorts.
CONCLUSIONS: There was no significant difference in mortality among A+C, A+D, and C+D combination treatment in patients without previous CVD. This finding was consistent across multi-national heterogeneous cohorts in real-world practice. PMID: 31642211 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - October 25, 2019 Category: Cardiology Tags: Korean Circ J Source Type: research

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
Publication date: Available online 24 October 2019Source: The LancetAuthor(s): Marc A Suchard, Martijn J Schuemie, Harlan M Krumholz, Seng Chan You, RuiJun Chen, Nicole Pratt, Christian G Reich, Jon Duke, David Madigan, George Hripcsak, Patrick B RyanSummaryBackgroundUncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in ...
Source: The Lancet - October 26, 2019 Category: General Medicine Source Type: research

Influence of dual ‐specificity protein phosphatase 5 on mechanical properties of rat cerebral and renal arterioles
In this study, we found that KO ofDusp5 did not alter body weights, kidney and brain weights, plasma glucose, and HbA1C levels. The expression of pERK is higher in the nucleus of primary VSMC isolated fromDusp5 KO rats.Dusp5 KO rats exhibited eutrophic vascular hypotrophy with smaller intracerebral parenchymal arterioles and renal interlobular arterioles without changing the wall ‐to‐lumen ratios. These arterioles fromDusp5 KO rats displayed higher myogenic tones, better distensibility, greater compliance, and less stiffness compared with arterioles from WT control rats. VSMC ofDusp5 KO rats exhibited a stronger contra...
Source: Physiological Reports - January 19, 2020 Category: Physiology Authors: Huawei Zhang, Chao Zhang, Yedan Liu, Wenjun Gao, Shaoxun Wang, Xing Fang, Ya Guo, Man Li, Ruen Liu, Richard J. Roman, Peng Sun, Fan Fan Tags: ORIGINAL RESEARCH Source Type: research

Risk Prediction of Coronary Flow Reserve is Strongly Influenced by the Burden of Coronary Calcification
Conclusions: Coronary flow reserve helps to risk stratify patients with CAC &gt 10. These findings have significant clinical implications but will need confirmation in larger studies.
Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Khan, M., Bravo, P., Vidula, M., Selvaraj, S., De Feria Alsina, A. E., Wiener, P., Szapary, H., Julien, H., Litt, H., Pryma, D., Dubroff, J., Guerraty, M. Tags: Technical Considerations and Clinical Application of Absolute Myocardial Blood Flow Source Type: research

Uncoupling Protein 2 as a pathogenic determinant and therapeutic target in cardiovascular and metabolic diseases
Curr Neuropharmacol. 2021 Apr 20. doi: 10.2174/1570159X19666210421094204. Online ahead of print.ABSTRACTUncoupling protein 2 (UCP2) is a mitochondrial protein that acts as an anion carrier. It is involved in the regulation of several processes including mitochondrial membrane potential, generation of reactive oxygen species within the inner mitochondrial membrane and calcium homeostasis. UCP2 expression can be regulated at different levels: genetic (gene variants), transcriptional [by peroxisome proliferator-activated receptors (PPARs) and microRNAs], and post-translational. Experimental evidence indicates that activation ...
Source: Current Neuropharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Rosita Stanzione Maurizio Forte Maria Cotugno Franca Bianchi Simona Marchitti Carla Letizia Busceti Francesco Fornai Speranza Rubattu Source Type: research